|3.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|5.||Blast Crisis (Blast Phase)
|1.||Cortes, Jorge: 219 articles (12/2015 - 03/2002)|
|2.||Kantarjian, Hagop: 177 articles (12/2015 - 02/2002)|
|3.||Hochhaus, Andreas: 115 articles (05/2015 - 01/2002)|
|4.||O'Brien, Susan: 111 articles (11/2015 - 04/2002)|
|5.||Kantarjian, Hagop M: 101 articles (10/2015 - 03/2002)|
|6.||Baccarani, Michele: 96 articles (09/2015 - 02/2002)|
|7.||Saglio, Giuseppe: 87 articles (10/2015 - 02/2002)|
|8.||Druker, Brian J: 83 articles (01/2015 - 01/2002)|
|9.||Jabbour, Elias: 79 articles (12/2015 - 01/2006)|
|10.||Breccia, Massimo: 78 articles (10/2015 - 04/2004)|
|1.||imatinib (Gleevec)FDA Link
01/01/2015 - "Imatinib mesylate (IM) remains the treatment of choice for chronic myeloid leukemia (CML) showing a remarkable efficacy and offers a perspective for long disease-free survival. "
11/01/2014 - "Imatinib mesylate (IM) has so far been the standard of care for treating chronic myeloid leukemia (CML), but the initial striking efficacy of this drug has been overshadowed by the development of clinical resistance, which may in part be caused by pharmacogenetic variability. "
02/01/2012 - "Targeted treatment of chronic myelogenous leukemia using imatinib has dramatically improved patient outcome. "
05/01/2011 - "Imatinib mesylate has shown remarkable efficacy in the treatment of patients in the chronic phase of chronic myeloid leukemia. "
02/01/2011 - "The advent of imatinib has dramatically improved outcomes in patients with chronic myelogenous leukemia (CML). "
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
09/01/2015 - "Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the outcome of chronic myelogenous leukemia in the chronic phase (CML-CP). "
02/01/2015 - "Tyrosine kinase inhibitors (TKIs) have dramatically improved the clinical outcomes of patients with chronic myeloid leukemia (CML) in the chronic phase. "
10/01/2014 - "The introduction of tyrosine kinase inhibitors has dramatically improved outcomes for many patients with chronic myeloid leukemia (CML), but some cases are resistant to this treatment. "
06/01/2014 - "The treatment of chronic myeloid leukemia (CML) with BCR-ABL1 tyrosine kinase inhibitors (TKIs) is highly effective in reducing disease burden and prolonging overall survival in the majority of patients. "
05/01/2014 - "Treatment of chronic myeloid leukemia has been revolutionized by the development of oral tyrosine kinase inhibitors that are highly effective in managing the disease when taken consistently. "
|3.||Interferon-alpha (Interferon Alfa)FDA Link
01/01/2004 - "In June 2002, he was diagnosed as having the chronic phase of chronic myelogenous leukemia (CML), and following treatment with interferon-alpha, he achieved hematological complete remission. "
01/01/2002 - "Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa."
04/01/1998 - "Interferon alfa (IFN-alpha) induces complete cytogenetic remission in a significant minority of patients with chronic myelogenous leukemia (CML). "
09/06/1997 - "[Fluctuating molecular remission in patients with chronic myeloid leukemia with long term complete cytogenetic response after alpha interferon treatment]."
12/01/1994 - "Interferon-alpha has been used for chronic myeloid leukemia patients and may achieve hematological and cytogenetic complete remission. "
|4.||dasatinib (BMS 354825)FDA Link
01/01/2012 - "Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia."
11/01/2011 - "Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features."
11/01/2010 - "We experienced a case of chronic myelogenous leukemia (CML) treated successfully with low-dose dasatinib (20 mg/day). "
01/01/2014 - "Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia."
03/01/2012 - "Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation."
11/01/1998 - "Interferon (IFN)-alpha may induce hematological remission in chronic myeloid leukemia (CML) patients, but only a small proportion of patients achieve a sustained, complete cytogenetic remission. "
07/01/1996 - "Additional translocation (9;12)(p13;q24.1) in newly diagnosed chronic myeloid leukemia: complete cytogenetic remission after interferon therapy."
02/15/1992 - "Interferon (IFN) therapy of early chronic myelogenous leukemia (CML) frequently produces partial or complete cytogenetic remission of the disease. "
06/01/2000 - "Interferon (IFN) is an effective treatment for chronic myeloid leukemia (CML) in chronic phases, and a number of in vitro antileukemic effects of IFN on CML cells have been reported. "
09/01/1992 - "Clonogenic assay is not predictive but reflects therapeutic efficacy of interferons in the treatment of chronic myelogenous leukemia."
|6.||4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)FDA Link
12/01/2013 - "Nilotinib is an effective option for the first-line treatment of chronic myeloid leukemia (CML) patients in chronic phase (CP). "
08/01/2013 - "Recently, nilotinib has been approved as a first-line treatment for chronic myelogenous leukemia in the US and Japan. "
09/01/2015 - "We report here the long-term, 6-year results of the first investigator-sponsored, GIMEMA multicenter phase 2, single-arm trial with nilotinib 400 mg twice daily as first-line treatment in 73 patients with chronic-phase chronic myeloid leukemia. "
09/01/2015 - "Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia."
01/01/2012 - "First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation."
|7.||Bcr-Abl tyrosine kinaseIBA
11/15/2013 - "BCR-ABL tyrosine kinase inhibitors (TKI) have dramatically improved therapy for chronic myelogenous leukemia (CML). "
12/01/2008 - "Bcr-Abl tyrosine kinase inhibitors (TKI) are effective in inducing remissions in chronic myelogenous leukemia (CML) patients but do not eliminate primitive CML hematopoietic cells. "
04/01/2012 - "The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). "
10/01/2015 - "Chronic myeloid leukemia (CML) is a disorder of hematopoietic stem cells caused by constitutive activation of the BCR/ABL tyrosine kinase. "
07/01/2015 - "Chronic myeloid leukemia (CML) is characterized by a constitutively active Bcr-Abl tyrosine kinase. "
09/01/2010 - "Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) is highly effective in controlling but not curing the disease. "
09/01/2010 - "Inhibition of BCR-ABL with kinase inhibitors has become a well-accepted strategy for targeted therapy of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) and has been shown to be highly effective in controlling the disease. "
02/01/2011 - "Chronic myeloid leukemia therapy has remarkably improved with the use of frontline BCR-ABL kinase inhibitors such that newly diagnosed patients have minimal disease manifestations or progression. "
10/01/2007 - "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia."
01/01/2005 - "[Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek]."
|9.||Busulfan (Busulfex)FDA Link
02/01/1989 - "[Appearance of chromosomally normal hemopoiesis during busulfan-induced remission in a case of Ph1 positive chronic myelogenous leukemia]."
01/01/1985 - "Survival in 73 patients with Ph1-positive chronic myelocytic leukemia was correlated with remission duration and leukocyte doubling time after initial treatment with busulfan and also, with clinical and laboratory features recorded at the time of diagnosis. "
01/01/1966 - "Prolonged remission in chronic myeloid leukemia after one course of busulfan."
07/01/1965 - "Prolonged remission in chronic myeloid leukemia after a single course of myleran."
05/01/1989 - "[A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan]."
|10.||Cytarabine (Cytosar-U)FDA LinkGeneric
08/01/2011 - "In patients with chronic myelogenous leukemia in the chronic phase, the combination of IFN-alfa + Ara-C demonstrated improved complete hematologic response, superior cytogenetic responses, and higher rates of 3- and 5-year survival than IFN-alfa alone. "
02/01/2007 - "A prospective randomized phase III study was performed to evaluate whether intensified cytarabine would induce a higher response rate and longer event-free interval as compared to low-dose cytarabine in chronic myeloid leukemia (CML). "
06/01/2000 - "In the in vitro part of our study, normal granulocyte-macrophage colony-forming unit (CFU-GM) cells as well as CFU-GM cells obtained from patients with chronic myeloid leukemia (CML) were incubated either with dFdC or Ara-C alone or with adequate concentrations of a combination of these drugs. "
09/29/2015 - "We have previously shown that ZNF224 exerts a specific proapoptotic role in chronic myelogenous leukemia (CML) K562 cells and contributes to cytosine arabinoside-induced apoptosis, by modulating WT1-dependent transcription of apoptotic genes. "
09/01/2005 - "Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia."
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
06/01/2000 - "For purposes of therapeutic decision making, we used quantitative polymerase chain reaction (PCR) for molecular follow-up of 55 patients with chronic myeloid leukemia (CML) in complete remission (CR) after allogeneic bone marrow transplantation (BMT) from HLA compatible donors. "
02/01/1999 - "Donor lymphocyte infusion (DLI) can restore complete remission in patients with chronic myelogenous leukemia (CML) who have relapsed after T-cell-depleted (TCD) allogeneic bone marrow transplantation (BMT). "
11/01/1998 - "Donor leukocyte infusions (DLI) have turned out to be an efficient way to re-establish complete remission (CR) in chronic myeloid leukemia (CML) patients relapsing after allogeneic bone marrow transplantation (BMT). "
03/01/1998 - "The authors report the case of a chronic myeloid leukemia (CML) patient submitted to allogenic bone marrow transplantation, who had probably never entered complete remission. "
12/01/1995 - "Donor lymphocyte infusions can reinduce complete remission in the majority of patients with chronic myelogenous leukemia (CML) who relapse into chronic phase after allogeneic bone marrow transplantation (BMT). "
10/01/1999 - "The infusion of lymphocytes from the original marrow donor (donor lymphocyte infusion [DLI]) reinduces complete remission in a high percentage of patients with chronic myeloid leukemia (CML) who relapse after allogeneic stem cell transplant, and thus, is probably the best initial approach to their management. "
01/01/2002 - "For patients who relapse with chronic myelogenous leukemia after matched sibling SCT, infusions of leukocytes collected from the original transplant donor will re-establish complete and durable remission in 60-80% of patients. "
09/01/2000 - "In the case of chronic myelogenous leukemia (CML), either allogeneic bone marrow transplant (BMT) or interferon-alpha2b (IFN-alpha2b) therapy can result in complete remission, but the mechanism for prolonged disease control is unknown and may involve immune anti-leukemic responses. "
06/01/1992 - "Forty-eight long-term disease-free chronic myelogenous leukemia (CML) patients, who had received unmanipulated allogeneic bone marrow transplants (BMT) for eradication of the Philadelphia (Ph1)-positive clone were studied by polymerase chain reaction (PCR), using a very sensitive PCR procedure and very stringent criteria for preventing and revealing contamination. "
04/01/2012 - "This retrospective case-matched study evaluated the efficacy of reduced intensity conditioning (RIC) regimen on early and late allogeneic transplant outcome in chronic myeloid leukemia (CML) patients. "
|3.||Stem Cell Transplantation
08/01/2012 - "Chronic myeloid leukemia (CML) represents a rare myeloproliferative disease among children where allogeneic stem cell transplantation (SCT) remains the curative gold standard. "
03/01/2004 - "Donor lymphocyte infusion (DLI) results in complete cytogenetic remission (CCR) of relapsed chronic-phase chronic myeloid leukemia (CML-CP) after allogeneic stem cell transplantation (SCT) in up to 80% of patients. "
05/15/2002 - "Donor lymphocyte infusion (DLI) can restore durable molecular remission in a high percentage of patients with chronic myeloid leukemia (CML) who have relapses after allogeneic stem cell transplantation, but for patients who do not respond survival is poor. "
04/01/2011 - "Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein."
07/01/2015 - "Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (alloSCT). "
|4.||Transplantation (Transplant Recipients)
03/01/1997 - "It was very effective in the treatment of chronic myelogenous leukemia recurring after marrow transplantation. "
01/01/2004 - "The experience of many years demonstrates high efficacy of ABM transplantation in the treatment of chronic myeloid leukemia. "
10/01/1995 - "bcr/abl chimeric transcript in patients in remission after marrow transplantation for chronic myeloid leukemia: higher frequency of detection and slower clearance in patients grafted in advanced disease as compared to patients grafted in chronic phase."
03/01/2007 - "To monitor the gene expression of BCR/ABL in chronic myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation with real-time RT-PCR for evaluating therapeutic efficacy and guiding further treatment. "
02/15/2002 - "Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia."
|5.||Drug Therapy (Chemotherapy)
04/01/2003 - "chronic phase of chronic myeloid leukemia (CML) or complete remission of other disease post chemotherapy (n=24), (4). "
05/01/1994 - "Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy. "
07/01/1993 - "Chronic myelogenous leukemia: progress in chemotherapy and evaluation of prognostic score 1. The German CML Study Group."
10/01/1990 - "In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. "
10/01/1990 - "Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion."